Spago Nanomedical AB (SE:SPAGO)

:SPAGO

SPAGO

Spago Nanomedical AB

RESEARCH TOOLSreports

Want to see SE:SPAGO full AI Analyst Report?

Spago Nanomedical AB (SPAGO) Price & Analysis

0 Followers

SPAGO Stock Chart & Stats

kr0.10

kr0.00(0.00%)

At close: Mar 06 4:00 PM EST

kr0.10

kr0.00(0.00%)

Day’s Range― - ―

52-Week Rangekr0.08 - kr0.33

Previous CloseN/A

Volume33.85K

Average Volume (3M)1.01M

Market Cap

kr88.54M

Enterprise Valuekr15.25M

Total Cash (Recent Filing)kr25.92M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding808,588,800

10 Day Avg. Volume1,158,815

30 Day Avg. Volume1,005,829

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.42

Price to Sales (P/S)99.92

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt balance sheet materially reduces refinancing and interest-rate risk for a pre-revenue biotech. This structural strength preserves flexibility to fund clinical programs through equity, partnerships or grants, supporting sustained R&D progress without fixed debt servicing burdens.

Narrowing Net LossesThe multi-year improvement in net loss indicates operational progress and potentially more efficient R&D spend. Over a 2–6 month horizon this trend suggests lower incremental cash burn risk, reducing financing frequency needs and de-risking program timelines if sustained.

Focused Nanomedicine PipelineA focused pipeline in nanoparticle diagnostics and targeted radiotherapy targets durable structural markets in oncology imaging and treatment. Clear program focus (SpagoPix, Tumorad) enables milestone-driven value creation and strategic partnerships common in biotech commercialization.

Bears Say

Persistent Cash BurnSustained negative operating cash flow shows the company remains cash-consuming and dependent on external capital. Over months this structural cash burn limits runway, increases dilution risk from new financings, and constrains the firm's ability to advance multiple clinical programs concurrently.

Sharp Revenue DeclineA steep, recent revenue decline highlights volatile or minimal commercial traction and weak near-term ability to self-fund operations. For a development-stage biotech, unpredictable revenue undermines financial resilience and increases reliance on successful financing or milestone payments.

Shrinking Equity And Negative ROEDeclining equity and sustained negative ROE reflect erosion of shareholder value from ongoing losses. Structurally, this limits the company's ability to raise capital on favorable terms, heightens dilution risk, and signals persistent profitability challenges that can slow long-term program advancement.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr0.08 and its highest was kr0.33 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr88.54M.

When is Spago Nanomedical AB’s upcoming earnings report date?

Spago Nanomedical AB’s upcoming earnings report date is Aug 20, 2026 which is in 71 days.

How were Spago Nanomedical AB’s earnings last quarter?

Spago Nanomedical AB released its earnings results on May 07, 2026. The company reported -kr0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.01.

Is Spago Nanomedical AB overvalued?

According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 808,588,800 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Spago Nanomedical AB reported an EPS of -kr0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spago Nanomedical AB

Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.